After some raucous after-hours trading shares of Dexcom at the moment are down a rather muted 6%. As we noted yesterday this was expected and, in our opinion, creates a buying opportunity. For all the pontificating when it comes to CGM the math is quite simple and we see Dexcom having a major advantage. Here’s why.
The Control IQ from Tandem and the Omnipod 5 from Insulet both work with the Dexcom sensor. These systems cannot function without the sensor. Think of it this way each Control IQ and Omnipod 5 patient uses on average 36 sensors per . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.